AZN.UK

10,194

+0.14%↑

GSK

1,375.5

+0.7%↑

INDV

825.5

-0.48%↓

AZN.UK

10,194

+0.14%↑

GSK

1,375.5

+0.7%↑

INDV

825.5

-0.48%↓

AZN.UK

10,194

+0.14%↑

GSK

1,375.5

+0.7%↑

INDV

825.5

-0.48%↓

AZN.UK

10,194

+0.14%↑

GSK

1,375.5

+0.7%↑

INDV

825.5

-0.48%↓

AZN.UK

10,194

+0.14%↑

GSK

1,375.5

+0.7%↑

INDV

825.5

-0.48%↓

Search

Haleon PLC

Gesloten

SectorGezondheidszorg

403.5 0.93

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

398.8

Max

406.8

Belangrijke statistieken

By Trading Economics

Inkomsten

-254M

231M

Verkoop

-21M

2.8B

K/W

Sectorgemiddelde

24.9

54.379

EPS

0.042

Dividendrendement

1.66

Winstmarge

8.373

Werknemers

24,561

EBITDA

-317M

399M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+2.77% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.66%

2.55%

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.9B

36B

Vorige openingsprijs

402.57

Vorige sluitingsprijs

403.5

Nieuwssentiment

By Acuity

50%

50%

195 / 382 Rangschikking in Healthcare

Haleon PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 apr 2025, 09:37 UTC

Acquisities, Fusies, Overnames

Haleon Acquires Chinese JV in $264 Million Deal

19 mrt 2025, 07:34 UTC

Acquisities, Fusies, Overnames

Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion

18 mrt 2025, 17:26 UTC

Acquisities, Fusies, Overnames

Pfizer to Dispose of Remaining Shareholding in Haleon

30 apr 2025, 08:33 UTC

Marktinformatie
Winsten

Haleon's Vitamins & Supplements Business Weakness in Focus Among Results -- Market Talk

30 apr 2025, 06:09 UTC

Winsten

Haleon Expects Macroeconomic Environment to Remain Challenging, Uncertain

30 apr 2025, 06:09 UTC

Winsten

Haleon Continues to Deliver Against Capital Allocation Priorities

30 apr 2025, 06:08 UTC

Winsten

Analysts Saw Haleon 1Q Organic Revenue Growth at 5.1%

30 apr 2025, 06:03 UTC

Winsten

Haleon Sees 2025 Adjusted Operating Profit Growth Ahead of Revenue Growth

30 apr 2025, 06:03 UTC

Winsten

Haleon Sees 2025 Organic Revenue Growth of 4%-6%

30 apr 2025, 06:03 UTC

Winsten

Haleon Backs 2025 View

30 apr 2025, 06:03 UTC

Winsten

Haleon 1Q Rev GBP2.85B

30 apr 2025, 06:01 UTC

Winsten

Haleon 1Q Organic Revenue Growth up 3.5%

29 apr 2025, 19:47 UTC

Winsten

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

15 apr 2025, 09:03 UTC

Acquisities, Fusies, Overnames

Haleon: Deal Expected to Close Within Next Three Mos

15 apr 2025, 09:03 UTC

Acquisities, Fusies, Overnames

Haleon Has Bought Last 12% Interest for GBP200M

15 apr 2025, 09:02 UTC

Acquisities, Fusies, Overnames

Haleon Bought 33% interest in December 2024

15 apr 2025, 09:02 UTC

Acquisities, Fusies, Overnames

Haleon Buys 33% Interest in Tianjin TSKF Pharmaceutical from Tianjin Pharmaceutical Da Ren Tang

15 apr 2025, 09:01 UTC

Acquisities, Fusies, Overnames

Haleon Buys 33% Interest in Tianjin TSKF Pharmaceutical

18 mrt 2025, 16:58 UTC

Acquisities, Fusies, Overnames

Haleon Intends to Cancel Purchased Ordinary Shares

18 mrt 2025, 16:57 UTC

Acquisities, Fusies, Overnames

Citigroup: Off-Market Transaction Will Close at Same Time as or Following Settlement of Offering

18 mrt 2025, 16:56 UTC

Acquisities, Fusies, Overnames

Citigroup: Off-Market Purchase Worth Approx GBP170M in Ordinary Shares

18 mrt 2025, 16:56 UTC

Acquisities, Fusies, Overnames

Citigroup: Haleon Agreed to Carry out Off-Market Purchase From Pfizer

18 mrt 2025, 16:52 UTC

Acquisities, Fusies, Overnames

Haleon Takes Note of Announcement

18 mrt 2025, 16:50 UTC

Acquisities, Fusies, Overnames

Citigroup: Haleon Won't Receive Any Net Proceeds From Offering

18 mrt 2025, 16:50 UTC

Acquisities, Fusies, Overnames

Citigroup: This Is Subject to Customary Closing Conditions

18 mrt 2025, 16:50 UTC

Acquisities, Fusies, Overnames

Citigroup: Pfizer Will Receive All of Net Proceeds From Offering

18 mrt 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Citigroup: Bookbuilding Period May Close at Any Time on Short Notice

18 mrt 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Citigroup: Bookbuilding Period Will Commence Immediately

18 mrt 2025, 16:49 UTC

Acquisities, Fusies, Overnames

Citigroup: Price Per Sale Share to Be Determined Through Accelerated Bookbuilding Process

18 mrt 2025, 16:48 UTC

Acquisities, Fusies, Overnames

Citigroup: Pfizer Intends to Sell Ordinary Shares to Institutional Investors

Peer Vergelijking

Prijswijziging

Haleon PLC Prognose

Koersdoel

By TipRanks

2.77% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 414.36Ā GBXĀ  2.77%

Hoogste 475Ā GBX

Laagste 315Ā GBX

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Haleon PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

6

Buy

4

Hold

1

Sell

Sentiment

By Acuity

195 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Haleon PLC

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.